Kiniksa Pharmaceuticals reported preliminary unaudited full-year 2024 ARCALYST net product revenue of $416.4 million. This represents approximately 79% year-over-year growth for the company's primary commercial product.
As of the end of 2024, approximately 13% of the multiple-recurrence target patient population for recurrent pericarditis was actively receiving ARCALYST therapy. This indicates continued market penetration and adoption of the treatment.
The company provided its initial 2025 ARCALYST net product revenue guidance, projecting sales to be between $560 million and $580 million. Kiniksa also reiterated its expectation to remain cash flow positive on an annual basis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.